Clinical Trial

Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study

Study acronym: SEAL-IT
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated June 7, 2021 (before its estimated March 2022 completion). Its status may not reflect the trial's current state.
Summary
The purpose of the study is to evaluate how well tolerated and effective an angiotensin receptor-neprilysin inhibitor (sacubitril-valsartan) is in patients with contemporary durable continuous flow left ventricular assist device (CF-LVAD) implantation compared to usual care oral vasodilator therapy.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2019-12-05; most recent amendment 2025-11-16.
Status change: Recruiting → Terminated 2024-10-02
Trial Details
NCT Number NCT04191681
Lead Sponsor The Cleveland Clinic
Conditions Stage D Heart Failure
Enrollment 50 participants
Start Date 2019-11-08
Primary Completion 2022-03 (estimated)
Study Completion 2022-12 (estimated)
Updated on ClinicalTrials.gov 2021-06-07